Table 1.

Patient’s clinical features.

	Case 1	Case 2	Case 3	Case 4	Case 5
Age (years), sex	60, male	33, female	61, male	59. male	55, male
Involved limb	Left arm and leg	Left leg	Right arm	Left arm	Left arm
FBDS	Yes	No	No	Yes	Yes
Days from weakness to FBDS onset	20	–	–	13	5
Short-term memory deterioration	Yes	No	Yes	Yes	No
Psychiatric disorder	No	No	Yes	Yes	No
EEG	Normal	Normal	Normal	Normal	Normal
Cranial MRI	T2-weighted and FLAIR hyper- intensity in the right hippocampus	Normal	T2-weighted and FLAIR hyper-intensity in the left hippocampus	Normal	Normal
CSF analysis	Normal	Normal	Normal	Normal	Normal
Anti-LGI1 positivity and titer	Serum 1:100 CSF 1:3.2	Serum 1:30 CSF1:10	Serum 1:30 CSF1:30	Serum 1:30 CSF1:10	Serum 1:100 CSF1:10
Immunotherapy	Methylprednisolone 500mg for 5 days, half decrement every 3 days, subsequent oral steroid tapering	Methylprednisolone 1000mg for 3 days, half decrement every 3 days, subsequent oral steroid tapering	Methylprednisolone 500mg for 5 days, half decrement every 3 days, subsequent oral steroid tapering	Methylprednisolone 500mg for 5 days, half decrement every 3 days, subsequent oral steroid tapering	Methylprednisolone 500mg for 7 days, half decrement every 3 days, subsequent oral steroid tapering
Outcome (follow-up)	Occasional paroxysmal limb weakness and FBDS (3 months). recurrence (20 months), FBDS reduced after methylprednisolone 500mg, weakness and FBDS disappeared (28 months)	Paroxysmal limb weakness disappeared (3 months)	Paroxysmal limb weakness disappeared (2 months) Short-term memory deterioration (4 months)	Occasional paroxysmal limb weakness and FBDS, normal mental status (2 months)	Paroxysmal limb weakness and FBDS disappeared, normal mental status (3 months)